Cargando…
The Safety of EXPAREL ® (Bupivacaine Liposome Injectable Suspension) Administered by Peripheral Nerve Block in Rabbits and Dogs
A sustained-release DepoFoam injection formulation of bupivacaine (EXPAREL, 15 mg/mL) is currently being investigated for postsurgical analgesia via peripheral nerve block (PNB). Single-dose toxicology studies of EXPAREL (9, 18, and 30 mg/kg), bupivacaine solution (Bsol, 9 mg/kg), and saline injecte...
Autores principales: | Richard, Brigitte M., Newton, Paul, Ott, Laura R., Haan, Dean, Brubaker, Abram N., Cole, Phaedra I., Ross, Paul E., Rebelatto, Marlon C., Nelson, Keith G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270427/ https://www.ncbi.nlm.nih.gov/pubmed/22363842 http://dx.doi.org/10.1155/2012/962101 |
Ejemplares similares
-
Safety Evaluation of EXPAREL (DepoFoam Bupivacaine) Administered by Repeated Subcutaneous Injection in Rabbits and Dogs: Species Comparison
por: Richard, Brigitte M., et al.
Publicado: (2011) -
EXPAREL® (Long-Acting Liposomal Bupivacaine) Use for Popliteal Nerve Block in Postoperative Pain Control after Ankle Fracture Fixation
por: Discepola, Patrick, et al.
Publicado: (2020) -
Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth
por: Mustafa, Hiba J., et al.
Publicado: (2020) -
Pharmacokinetic Compatibility Study of Lidocaine with EXPAREL in Yucatan Miniature Pigs
por: Richard, Brigitte M., et al.
Publicado: (2011) -
Comparative growth dynamics of bacterial and fungal contaminants in bupivacaine liposomal injectable suspension, bupivacaine 0.5%, and propofol
por: Wallace, Amber, et al.
Publicado: (2023)